Organisms of the Mycobacterium avium complex (MAC) cause disseminated disease in patients with AIDS, and evidence points to the gastrointestinal tract as the major route of infection. Since MAC can bind to and invade intestinal mucosal cells, we examined whether subinhibitory concentrations of antibiotics which have anti-MAC activity in vitro affect the interaction between MAC and HT-29 intestinal mucosal cells. MAC isolates were exposed to subinhibitory concentrations of rifabutin (MIC, 2.6 ,ug/ml), sparfloxacin (MIC, 8.4 ,ug/ml), or azithromycin (MIC, 32 ,ug/ml) for 30 to 120 min, washed, and incubated with HT-29 cell monolayers for 2 h at 4°C. HT-29 cell monolayers were then washed to remove unbound bacteria and were subsequently lysed. The number of MAC isolates that bound to the HT-29 cells was determined by plating the cell lysate onto 7H10 agar. Preincubation of the MAC isolates with rifabutin at concentrations of 1 and 2 ,ig/ml reduced MAC binding to HT-29 cells by 80 to 90%, while MAC exposed to sparfloxacin at 1 and 7 ,ug/ml inhibited binding by 77 to 93%. Azithromycin at concentrations of 2, 10, and 30 ,ug/ml had no effect on MAC binding to HT-29 cells. Inhibition of MAC binding to the gastrointestinal mucosa may be one underlying mechanism for the prophylactic effects of rifabutin and quinolones.
Disseminated infection with the Mycobacterium avium complex (MAC) is the most common cause of bacteremia in patients with AIDS and develops in up to 80% of these patients (7, 8) . In patients with AIDS, MAC is found in large numbers in the reticuloendothelial system and bone marrow (16) . Survival of AIDS patients with disseminated MAC disease has been shown to be approximately one-half that of those patients at a similar stage of AIDS but without MAC disease (11, 13) .
More recently, treatment regimens with significant activity against MAC have been identified and are routinely used in the management of this opportunistic infection (4, 17) . However, relapses and the emergence of resistance have occurred, and none of the treatment regimens appears to eradicate the infection. In patients with AIDS, MAC is chiefly acquired by the gastrointestinal route, and recent studies have demonstrated the ability of the mycobacteria to bind and invade intestinal mucosal cells (lb, 12) .
There is an urgent need to prevent MAC infection. Recent work by Nightingale and colleagues (14) (2) .
Rifabutin was provided by Farmitalia Carlos Erba (Milan, Italy). It was dissolved in ethanol and was subsequently diluted in water to the desirable concentrations. Sparfioxacin was provided by Parke-Davis (Ann Arbor, Mich.) and was dissolved and diluted in water. Azithromycin was a gift from Pfizer Research Laboratories, Inc. (Groton, Conn.), and was also dissolved and subsequently diluted in water. The MICs of rifabutin, sparfioxacin, and azithromycin for MAC 101, as determined by the radiometric method (BACTEC; Johnston Laboratories, Cockeysville, Md.) as described previously (9), were 2.6, 8.4, and 32 jig/ml, respectively.
The HT-29 human colon carcinoma cell line was obtained from the American Type Culture Collection (Rockville, Md.) and was maintained in McCoy 5A tissue culture medium without glucose (Sigma Chemical Co., St. Louis, Mo.) but supplemented with 1% galactose, 2 mM L-glutamine, and 5% fetal bovine serum (Sigma). The cell line was used between passages 30 and 35 in all assays. Monolayers were seeded with 105 cells and were allowed to grow overnight to semiconfluence.
The binding assay was carried out by the method described by Isberg and Falkow (10) and modified by us (lb) . Briefly, the medium overlaying the HT-29 cell monolayer was replaced with 1 ml of ice-cold tissue culture medium. MAC was used without preexposure to antibiotics or following exposure to different concentrations of antibiotics for 30 min, 1 h, or 2 h at NOTES individual wells of HT-29 cell monolayers, and the dishes were placed at 4°C for 120 min. Control wells without mammalian cells were prepared similarly to measure nonspecific bacterial adherence to the plastic. After the incubation period, each well was rinsed four times with 1 ml of ice-cold HBSS (pH 7.4) to remove nonadherent bacteria. Monolayers were subsequently treated with 0.5 ml of 0.1% Triton X-100 (Sigma) in sterile water for 10 min. Finally, 0.5 ml of 7H9 broth was added to each sample, and the bacteria were harvested. Adherent bacteria were quantitated by plating the bacteria onto 7H10 agar plates for CFU determinations.
The assays were repeated three times, and the results were expressed as means ± standard deviations. The significance of the differences between experimental groups and controls at the same time point were analyzed by Student's t test.
As shown in Table 1 and colleagues (3), using a thymectomized CD4 -T-celldeficient C57BL/6J mouse model and a model in which a rat was treated with cyclosporin, respectively, found that rifabutin is active against MAC in vivo. Using the beige mouse model, we have found that rifabutin alone at different concentrations and in combination with ethambutol has limited activity against MAC (1) . This discrepancy in the results, however, may be attributed to the susceptibilities of the challenge organisms used in the respective studies. Recent double-blind, placebocontrolled trials in patients with AIDS have demonstrated the efficacy of rifabutin in preventing or delaying MAC bacteremia in that patients population (14) .
Azithromycin has been shown to be an effective therapeutic agent for MAC disease in humans (17) . Furthermore, experiments in mice and rats demonstrated that azithromycin is effective when used prophylactically against MAC (la, 3) . However, our data suggest that the prophylactic effect of azithromycin is not due to the inhibition of MAC binding to the intestinal mucosal cells. In fact, similar data were obtained MAC can bind to and invade intestinal cells as an initial event in the pathogenesis of systemic infection. Recent evidence suggests that MAC binds to receptors on the membrane of epithelial mucosal cells (lb) . Antibiotics which can inhibit the synthesis of proteins involved in the binding process may influence the ability of MAC to cause disease in patients with AIDS.
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